Holen Sie sich die Stockscreener-App
1.16
22.51%
0.2131
Handel nachbörslich:
1.21
0.05
+4.31%
Tenaya Therapeutics Inc Aktie (TNYA) Neueste Nachrichten
Tenaya Therapeutics Surges Forward: What’s Next? - StocksToTrade
Is Tenaya Therapeutics Inc. a defensive stockJuly 2025 EndofMonth & Fast Exit Strategy with Risk Control - newsyoung.net
Tenaya Therapeutics Reports Q2 2025 Financial Results - TipRanks
Elliott Wave Theory Predicts Pullback in Tenaya Therapeutics Inc.2025 Risk Factors & Momentum Based Trading Signals - thegnnews.com
Can Tenaya Therapeutics Inc. reach all time highs this yearTop Stocks for Quick Doubling - kangso.co.kr
A Quick Look at Today's Ratings for Tenaya Therapeutics(TNYA.US), With a Forecast Between $3 to $5 - 富途牛牛
Tenaya Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference - GlobeNewswire
Heart Disease Cure? Tenaya CEO Reveals Latest Therapeutic Developments at Major Growth Conference - Stock Titan
Strong Financial Position and Promising Clinical Progress Drive Buy Rating for Tenaya Therapeutics - TipRanks
Tenaya Therapeutics shares rise 6.67% premarket after positive safety reviews for TN-201 and TN-401 gene therapy trials. - AInvest
Tenaya Therapeutics Posts Smaller Losses And Advances Gene Trials - Finimize
Tenaya (TNYA) Q2 Loss Narrows 59% - The Globe and Mail
Tenaya Therapeutics reports Q2 EPS (14c), consensus (19c) - TipRanks
Tenaya Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update - The Manila Times
Tenaya's Gene Therapies Clear Key Safety Hurdles: Q4 Data Readouts Coming for Heart Disease Treatments - Stock Titan
What are the technical indicators suggesting about Tenaya Therapeutics Inc.Achieve consistent profits with proven methods - Jammu Links News
What analysts say about Tenaya Therapeutics Inc. stockPhenomenal wealth increase - Jammu Links News
Why is Tenaya Therapeutics Inc. stock attracting strong analyst attentionCapitalize on fast-moving stock opportunities - Jammu Links News
How strong is Tenaya Therapeutics Inc. company’s balance sheetMaximize your gains with professional insights - Jammu Links News
Does Tenaya Therapeutics Inc. stock perform well during market downturnsMarket-beating returns - Jammu Links News
What are the latest earnings results for Tenaya Therapeutics Inc.Market-leading capital gains - Jammu Links News
What is Tenaya Therapeutics Inc. company’s growth strategyCapitalize on market shifts before others do - Jammu Links News
What makes Tenaya Therapeutics Inc. stock price move sharplyMaximize gains with timely market signals - Jammu Links News
What is the dividend policy of Tenaya Therapeutics Inc. stockBoost your wealth with consistent growth stocks - Jammu Links News
How sentiment analysis helps forecast Tenaya Therapeutics Inc.ROI Focused Setup Screener With Exit Markers - Newser
Can Tenaya Therapeutics Inc. hit a new high this monthMarket Opportunity Tracker for Swing Traders - Newser
Is Tenaya Therapeutics Inc. stock bottoming outVolume Confirmed Setup with Entry Confidence - Newser
How to read the order book for Tenaya Therapeutics Inc.Free Consistent Profit Pattern Recognition Tools - Newser
Advanced analytics toolkit walkthrough for Tenaya Therapeutics Inc.Technical Confirmation System with Signal Alerts - Newser
How does Tenaya Therapeutics Inc. generate profit in a changing economyChart Pattern Strategy To Watch Now - Jammu Links News
Tenaya Therapeutics, Inc. (NASDAQ:TNYA) Receives Average Rating of “Buy” from Analysts - Defense World
Using economic indicators to assess Tenaya Therapeutics Inc. potentialReal Market Tracker with Price Action Tools - Newser
Will Tenaya Therapeutics Inc. stock go up soonFundamental Forecast for Undervalued Stocks - Newser
What institutions are buying Tenaya Therapeutics Inc. stock nowFundamental Forecast for Undervalued Stocks - Newser
Intrinsic Value of Tenaya Therapeutics Inc. Stock: Is It Undervalued or OvervaluedDaily Breakout List with Smart Filters - Newser
Kalaris Therapeutics shares rise 1.49% intraday after Tenaya Therapeutics, Inc. received positive safety endorsements for its cardiovascular gene therapy clinical trials. - AInvest
Published on: 2025-07-30 22:05:21 - metal.it
Tenaya Receives Positive Safety Reviews from Independent - GlobeNewswire
Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies By Investing.com - Investing.com South Africa
Tenaya Therapeutics stock rises after positive safety reviews for heart gene therapies - Investing.com Nigeria
Gene Therapy's Cardiovascular Revolution: Why Tenaya Therapeutics Is a High-Conviction Bet in 2025 - AInvest
Tenaya completes enrollment in both dose cohorts for HCM gene therapy - Investing.com
Tenaya Receives Positive Safety Reviews from Independent DSMBs to Advance Both TN-201 and TN-401 Gene Therapy Clinical Trials as Designed - The Manila Times
Breakthrough: Tenaya's Dual Heart Disease Gene Therapies Pass Major Safety Milestone - Stock Titan
How Resilient Is Tenaya Therapeutics Inc. Stock During Economic DownturnsEarly Buy Opportunity with Chart Triggers - Newser
0.44%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):